航空航天医学杂志
航空航天醫學雜誌
항공항천의학잡지
AEROSPACE MEDICINE
2015年
4期
401-403
,共3页
心肌梗死%血小板聚集抑制剂%血管成形术%经腔%经皮冠状动脉
心肌梗死%血小闆聚集抑製劑%血管成形術%經腔%經皮冠狀動脈
심기경사%혈소판취집억제제%혈관성형술%경강%경피관상동맥
MI%Platelet Aggregation Inhibitors%Angioplasty%Transluminal%Percutaneous Coronary
目的:探讨未行早期介入治疗的急性非ST段抬高心肌梗死( NSTEMI)患者替罗非班应用的有效性和安全性。方法选取2013年1月~2014年9月收治的未行早期再灌注治疗NSTEMI患者80例,随机分为对照组和研究组,每组40例,对照组行常规治疗,研究组在对照组治疗方案基础上加用替罗非班治疗,观察两组间死亡、再次心肌梗死及左室射血分数等心血管临床事件的变化及出血情况。结果对照组1例脑出血死亡(P>0.05),研究组无死亡及严重出血事件,随诊再次发生心肌梗死2例,射血分数<40%者3例,明显优于对照组( P<0.05)。结论研究结果表明替罗非班一定程度上改善了NSTEMI患者的临床症状和左室射血功能,但对于主要不良心血管事件的发生率无明显改善。对未行急诊再灌注治疗的STEMI的最佳药物治疗方案制订提供了一定的临床依据,但仍需进一步探索。
目的:探討未行早期介入治療的急性非ST段抬高心肌梗死( NSTEMI)患者替囉非班應用的有效性和安全性。方法選取2013年1月~2014年9月收治的未行早期再灌註治療NSTEMI患者80例,隨機分為對照組和研究組,每組40例,對照組行常規治療,研究組在對照組治療方案基礎上加用替囉非班治療,觀察兩組間死亡、再次心肌梗死及左室射血分數等心血管臨床事件的變化及齣血情況。結果對照組1例腦齣血死亡(P>0.05),研究組無死亡及嚴重齣血事件,隨診再次髮生心肌梗死2例,射血分數<40%者3例,明顯優于對照組( P<0.05)。結論研究結果錶明替囉非班一定程度上改善瞭NSTEMI患者的臨床癥狀和左室射血功能,但對于主要不良心血管事件的髮生率無明顯改善。對未行急診再灌註治療的STEMI的最佳藥物治療方案製訂提供瞭一定的臨床依據,但仍需進一步探索。
목적:탐토미행조기개입치료적급성비ST단태고심기경사( NSTEMI)환자체라비반응용적유효성화안전성。방법선취2013년1월~2014년9월수치적미행조기재관주치료NSTEMI환자80례,수궤분위대조조화연구조,매조40례,대조조행상규치료,연구조재대조조치료방안기출상가용체라비반치료,관찰량조간사망、재차심기경사급좌실사혈분수등심혈관림상사건적변화급출혈정황。결과대조조1례뇌출혈사망(P>0.05),연구조무사망급엄중출혈사건,수진재차발생심기경사2례,사혈분수<40%자3례,명현우우대조조( P<0.05)。결론연구결과표명체라비반일정정도상개선료NSTEMI환자적림상증상화좌실사혈공능,단대우주요불양심혈관사건적발생솔무명현개선。대미행급진재관주치료적STEMI적최가약물치료방안제정제공료일정적림상의거,단잉수진일보탐색。
Objective To study the efficiency and safety of Tirofiban for patients with NSTEMI and non -invasive therapy.Methods 80 patients with NSTEMI and without earlier reperfusion therapy treated from January 2013 to Sep-tember 2014 in our hospital were selected and randomly divided into control group and research group , 40 cases each group.The control group received the conventional treatment while the research group received the conventional treatment combined with Tirofiban; the variations and hemorrhage of cardiovascular events like death , MI and LVEF were ob-served.Results One patient of control group was died of cerebral hemorrhage ( P>0.05 ); the research group had no death or major bleeding case .In the periodic checkup , there were 2 cases died of MI and 3 cases with LVEF (<40%) (P<0.05).Conclusions The findings indicate that Tirofiban can partially improve the clinical symptoms and left ven -tricular ejection for patients with NSTEMI .The major adverse cardiovascular events were not greatly improved .It pro-vides the clinical basis to make the best medication treatment for patients with STEMI and without reperfusion therapy . However , it needs to be further explored .